penta-refractory multiple myeloma

May 9, 2018May 10, 2018

Selinexor May Bring Hope to Heavily Treated Myeloma Patients, Trial Results Show

News

A quarter of heavily treated patients with penta-refractory multiple myeloma responded to Karyopharm‘s investigative oral therapy selinexor (KPT-330), according to top-line data from a Phase 2 study. The results bring ... Read more

April 13, 2018April 13, 2018

Selinexor Gains FDA Fast Track Designation for Refractory Multiple Myeloma Patients

News

Selinexor, the lead oral therapy developed by Karyopharm Therapeutics, received Fast Track designation by the U.S. Food and Drug Administration (FDA), for the treatment of refractory multiple myeloma patients — those ... Read more